Key result
Istaroxime rescues calcium dysregulation and improves cardiac relaxation in zebrafish with PLN R14del cardiomyopathy.
Why the study?
Little is known about the physiological processes preceding Phospholamban p.Arg14del cardiomyopathy, and specific drug treatment is currently lacking.
Does istaroxime improve calcium dysregulation and cardiac function in a zebrafish model of Phospholamban p.Arg14del cardiomyopathy?
Does istaroxime improve calcium dysregulation and cardiac function in a zebrafish model of Phospholamban p.Arg14del cardiomyopathy?
Istaroxime ameliorates calcium dysregulation and improves cardiac relaxation in a zebrafish model of Phospholamban p.Arg14del cardiomyopathy, suggesting a potential therapeutic avenue for this specific genetic mutation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for istaroxime in PLN-R14del models; leaves open translation to patients.
The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca 2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca 2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca 2+ level, slower Ca 2+ transient decay and longer Ca 2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca 2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Kamel et al. (2021) studied Phospholamban R14del cardiomyopathy. Istaroxime vs. Baseline / Wild-type was evaluated on Calcium transient amplitude and action potential duration alternans. Istaroxime treatment ameliorated in vivo calcium dysregulation, rescued cellular action potential duration alternans, and improved cardiac relaxation in a zebrafish model of phospholamban R14del cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: